echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > To Biao Hengrui and Sanofi!

    To Biao Hengrui and Sanofi!

    • Last Update: 2021-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      Medical Network News, May 8 Recently, the official website of the State Food and Drug Administration showed that the docetaxel injection of Sichuan Meida Kangjiale Pharmaceutical was approved as a supplementary application.
    According to data from Meinenet, the sales of terminal docetaxel injections in China's public medical institutions exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
    71% in 2020.
    Docetaxel injection has more than 20 manufacturers.
    Among them, Jiangsu Hengrui Medicine has the largest market share, followed by Sanofi.
     
      Statistics show that docetaxel is paclitaxel class of anti- cancer drugs, by interfering with the cells between mitosis and cell division of functions necessary microtubule network sky antitumor effect.
    Docetaxel injection was first developed and produced by the French Rhone Planck Lean Company (now Sanofi-Aventis).
     
      Sales of terminal docetaxel injections in public medical institutions in China in recent years
      Source: Terminal competition landscape of China's public medical institutions
     
      According to data from Meinenet, in 2019, the sales of terminal docetaxel injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 4 billion yuan, a year-on-year decrease of 12.
    71% in 2020.
    .
    There are more than 20 manufacturers of docetaxel injection, including Jiangsu Hengrui
    Pharmaceutical , Sanofi, Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Osaikang, etc.
    Among them, Jiangsu Hengrui Pharmaceutical has the largest market share, and Sanofi follows closely.
    Rear.
     
      
    Source: MED2.
    0 Chinese Drug Evaluation Database
     
      In terms of consistency evaluation, docetaxel injection has been reviewed by 6 companies .
    Among them, Sichuan Huiyu Pharmaceutical has been approved for production of generic 4 types, which is deemed to have been reviewed; Jiangsu Hengrui Pharmaceutical and Zhengda Tianqing Pharmaceutical The Group, Qilu Pharmaceutical, Yangtze River Pharmaceutical Group, and Sichuan Meida Kangjiale Pharmaceutical have all been approved as supplementary applications.
    In addition, supplementary applications for consistency evaluation of three companies including Jiangsu Aosaikang Pharmaceutical and Shanghai Chuangnuo Pharmaceutical are under review and approval.
    Yangzijiang Pharmaceutical Group and Luoxin Biotechnology have submitted their application for listing in 4 categories of imitations and are under review and approval.
    Once approved, it is deemed to have been reviewed.
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
      Medical Network News, May 8 Recently, the official website of the State Food and Drug Administration showed that the docetaxel injection of Sichuan Meida Kangjiale Pharmaceutical was approved as a supplementary application.
    According to data from Meinenet, the sales of terminal docetaxel injections in China's public medical institutions exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
    71% in 2020.
    Docetaxel injection has more than 20 manufacturers.
    Among them, Jiangsu Hengrui Medicine has the largest market share, followed by Sanofi.
     
      Statistics show that docetaxel is paclitaxel class of anti- cancer drugs, by interfering with the cells between mitosis and cell division of functions necessary microtubule network sky antitumor effect.
    Docetaxel injection was first developed and produced by the French Rhone Planck Lean Company (now Sanofi-Aventis).
     
      Sales of terminal docetaxel injections in public medical institutions in China in recent years
      Source: Terminal competition landscape of China's public medical institutions
     
      According to data from Meinenet, in 2019, the sales of terminal docetaxel injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 4 billion yuan, a year-on-year decrease of 12.
    71% in 2020.
    .
    There are more than 20 manufacturers of docetaxel injection, including Jiangsu Hengrui
    Pharmaceutical , Sanofi, Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Osaikang, etc.
    Among them, Jiangsu Hengrui Pharmaceutical has the largest market share, and Sanofi follows closely.
    Rear.
     
      
    Source: MED2.
    0 Chinese Drug Evaluation Database
     
      In terms of consistency evaluation, docetaxel injection has been reviewed by 6 companies .
    Among them, Sichuan Huiyu Pharmaceutical has been approved for production of generic 4 types, which is deemed to have been reviewed; Jiangsu Hengrui Pharmaceutical and Zhengda Tianqing Pharmaceutical The Group, Qilu Pharmaceutical, Yangtze River Pharmaceutical Group, and Sichuan Meida Kangjiale Pharmaceutical have all been approved as supplementary applications.
    In addition, supplementary applications for consistency evaluation of three companies including Jiangsu Aosaikang Pharmaceutical and Shanghai Chuangnuo Pharmaceutical are under review and approval.
    Yangzijiang Pharmaceutical Group and Luoxin Biotechnology have submitted their application for listing in 4 categories of imitations and are under review and approval.
    Once approved, it is deemed to have been reviewed.
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
      Medical Network News, May 8 Recently, the official website of the State Food and Drug Administration showed that the docetaxel injection of Sichuan Meida Kangjiale Pharmaceutical was approved as a supplementary application.
    According to data from Meinenet, the sales of terminal docetaxel injections in China's public medical institutions exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
    71% in 2020.
    Docetaxel injection has more than 20 manufacturers.
    Among them, Jiangsu Hengrui Medicine has the largest market share, followed by Sanofi.
     
      Statistics show that docetaxel is paclitaxel class of anti- cancer drugs, by interfering with the cells between mitosis and cell division of functions necessary microtubule network sky antitumor effect.
    Docetaxel injection was first developed and produced by the French Rhone Planck Lean Company (now Sanofi-Aventis).
    Tumor tumor tumor
     
      Sales of terminal docetaxel injections in public medical institutions in China in recent years
      Source: Terminal competition landscape of China's public medical institutions
     
      According to data from Meinenet, in 2019, the sales of terminal docetaxel injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 4 billion yuan, a year-on-year decrease of 12.
    71% in 2020.
    .
    There are more than 20 manufacturers of docetaxel injection, including Jiangsu Hengrui
    Pharmaceutical , Sanofi, Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Osaikang, etc.
    Among them, Jiangsu Hengrui Pharmaceutical has the largest market share, and Sanofi follows closely.
    Rear.
    Hospital Hospital Hospital Medicine Medicine Medicine
     
      
    Source: MED2.
    0 Chinese Drug Evaluation Database
     
      In terms of consistency evaluation, docetaxel injection has been reviewed by 6 companies .
    Among them, Sichuan Huiyu Pharmaceutical has been approved for production of generic 4 types, which is deemed to have been reviewed; Jiangsu Hengrui Pharmaceutical and Zhengda Tianqing Pharmaceutical The Group, Qilu Pharmaceutical, Yangtze River Pharmaceutical Group, and Sichuan Meida Kangjiale Pharmaceutical have all been approved as supplementary applications.
    In addition, supplementary applications for consistency evaluation of three companies including Jiangsu Aosaikang Pharmaceutical and Shanghai Chuangnuo Pharmaceutical are under review and approval.
    Yangzijiang Pharmaceutical Group and Luoxin Biotechnology have submitted their application for listing in 4 categories of imitations and are under review and approval.
    Once approved, it is deemed to have been reviewed.
    Enterprise business enterprise
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.